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Soluble guanylate cyclase (sGC) is a signal-transduction
enzyme activated by nitric oxide (NO) and plays a key role
in a variety of physiological processes such as vasodilata-
tion, antiaggregation, antiproliferation and neuronal sig-
naling as well as in a variety of disorders of these
functions. Current therapies that involve the use of
organic nitrates and other NO donors have limitations,
including non-specific interactions of NO with various
biomolecules and lack of response and the development
of tolerance [1,2]. Compounds that activate sGC in an
NO-independent manner might therefore provide consid-
erable therapeutic advantages.
High throughput screening led to the identification of a
series of dicarboxlic acids as potent sGC activators. Lead
structure 1 showed promising in vitro potency (sGC over-
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Discovery of sGC activators via ultra-high throughput screening using sGC-overexpressing CHO cell linesFigure 1
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expressing CHO-cells and relaxation of precontracted rab-
bit arteria saphena rings) and haemodynamic effects in
anaesthetized rats (Fig. 1). Extensive chemical derivatiza-
tion resulted in conclusive structure activity relationships,
which will be presented. Eventually, optimization led to
the discovery of BAY 58–2667, a highly potent sGC acti-
vator which is currently in clinical trials in patients for the
treatment of acute decompensated chronic heart failure.
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